Department of Oncology, Odense University Hospital, Denmark.
Eur J Cancer. 2013 Jan;49(1):98-105. doi: 10.1016/j.ejca.2012.07.017. Epub 2012 Aug 19.
Pancreatic cancer (PC) is associated with a dismal prognosis. Few studies have examined characteristics and outcome in an unselected population-based cohort of PC patients. Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC.
All cases diagnosed with PC between 2007 and 2009 in the Region of Southern Denmark (pop: 1,200,000) were prospectively registered. Patient characteristics including performance status, information about haematology, liver function and therapy were retrieved from patient charts, and used to compare differently treated and untreated groups.
Six-hundred-eighteen cases were registered as PC; 25 of which did not have adenocarcinomas. Patients were divided in 3 clinical groups based on initial therapy; group 1: resection (n=64), group 2: chemotherapy or chemo-radiotherapy (n=191), group 3: no tumour directed therapy (n=324). Median survival (mOS) (95% confidence interval (CI)) in the three groups was 25.7 months (18-30), 8.1 months (7.0-9.5) and 1.1 months (1.0-1.3) respectively. Three percent of patients participated in clinical trials. An evaluation of baseline factors prognostic value suggested that treated patients differed significantly from non-treated patients.
This study reports survival in treated groups comparable to results obtained from clinical trials with highly selected patients. However the majority of patients with PC do not receive cancer directed therapy. This group was significantly different in several baseline factors, which could suggest a different biology. Improving the outcome of PC patients calls for research into the large group of untreated patients, as only a minority of patients receive cancer directed therapy.
胰腺癌(PC)的预后较差。很少有研究在未选择的基于人群的 PC 患者队列中检查特征和结果。因此,我们研究了一个完整的 PC 患者队列中患者的基线特征、治疗选择和生存情况。
在丹麦南部地区(人口 120 万),前瞻性地登记了 2007 年至 2009 年间诊断为 PC 的所有病例。从患者病历中检索了患者特征,包括表现状态、血液学、肝功能和治疗信息,并用于比较不同治疗和未治疗组。
共登记了 618 例 PC 病例,其中 25 例未患有腺癌。根据初始治疗,患者被分为 3 个临床组;组 1:切除(n=64),组 2:化疗或放化疗(n=191),组 3:无肿瘤定向治疗(n=324)。三组的中位生存时间(mOS)(95%置信区间(CI))分别为 25.7 个月(18-30)、8.1 个月(7.0-9.5)和 1.1 个月(1.0-1.3)。有 3%的患者参加了临床试验。对基线因素预后价值的评估表明,接受治疗的患者与接受高度选择的临床试验的患者有显著差异。然而,大多数 PC 患者未接受癌症定向治疗。该组在几个基线因素上有显著差异,这可能表明其生物学特征不同。为了提高 PC 患者的治疗效果,需要研究未接受治疗的患者,因为只有少数患者接受癌症定向治疗。